Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

5.98

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

0.29

Price

8.26

Target Price

9.57

Analyst Recom

1.5

Performance Q

76.71

Relative Volume

0.96

Beta

1.55

Ticker: ADPT




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-01-23ADPT8.120.130.021119
2025-01-24ADPT7.990.130.041164
2025-01-27ADPT7.720.130.221186
2025-01-28ADPT7.860.140.291233
2025-01-29ADPT7.710.140.081240
2025-01-30ADPT7.860.140.441247
2025-01-31ADPT7.740.140.021280
2025-02-03ADPT7.660.150.001277
2025-02-04ADPT7.380.150.001286
2025-02-05ADPT8.050.140.431290
2025-02-06ADPT8.010.150.001292
2025-02-07ADPT7.840.150.371298
2025-02-10ADPT7.690.150.001338
2025-02-11ADPT7.80.130.061472
2025-02-12ADPT7.550.132.941495
2025-02-13ADPT8.520.210.251617
2025-02-14ADPT8.350.220.021717
2025-02-18ADPT8.260.270.091512
2025-02-19ADPT8.380.260.171549
2025-02-20ADPT8.340.260.051645
2025-02-21ADPT8.270.264.051643
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-01-23ADPT8.1319.9- -1.11
2025-01-24ADPT8.0019.9- -1.11
2025-01-27ADPT7.7219.9- -1.11
2025-01-28ADPT7.8619.9- -1.11
2025-01-29ADPT7.7119.9- -1.11
2025-01-30ADPT7.8619.9- -1.11
2025-01-31ADPT7.7419.9- -1.11
2025-02-03ADPT7.7019.9- -1.11
2025-02-04ADPT7.3719.9- -1.11
2025-02-05ADPT8.0519.9- -1.11
2025-02-06ADPT8.0019.9- -1.11
2025-02-07ADPT7.8419.9- -1.11
2025-02-10ADPT7.6819.9- -1.11
2025-02-11ADPT7.8019.9- -1.11
2025-02-12ADPT7.5519.9- -1.11
2025-02-13ADPT8.5315.3- -0.86
2025-02-14ADPT8.339.0- -0.91
2025-02-18ADPT8.276.5- -0.91
2025-02-19ADPT8.376.5- -0.91
2025-02-20ADPT8.347.4- -0.92
2025-02-21ADPT8.267.4- -0.92
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-01-23ADPT-0.561.806.44
2025-01-24ADPT-0.561.806.44
2025-01-27ADPT-0.561.776.44
2025-01-28ADPT-0.561.776.06
2025-01-29ADPT-0.561.776.06
2025-01-30ADPT-0.561.776.06
2025-01-31ADPT-0.561.776.06
2025-02-03ADPT-0.564.356.06
2025-02-04ADPT-0.564.356.06
2025-02-05ADPT-0.564.356.06
2025-02-06ADPT-0.564.356.06
2025-02-07ADPT-0.564.356.06
2025-02-10ADPT-0.56-20.446.06
2025-02-11ADPT-0.56-20.446.06
2025-02-12ADPT-0.56-20.445.98
2025-02-13ADPT-0.56-20.445.98
2025-02-14ADPT-0.56-20.445.98
2025-02-18ADPT-0.55-19.825.98
2025-02-19ADPT-9.27-19.825.98
2025-02-20ADPT-9.27-19.825.98
2025-02-21ADPT-9.27-19.825.98
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.29

Avg. EPS Est. Next Quarter

-0.24

Insider Transactions

-9.27

Institutional Transactions

-19.82

Beta

1.55

Average Sales Estimate Current Quarter

42

Average Sales Estimate Next Quarter

47

Fair Value

Quality Score

37

Growth Score

45

Sentiment Score

97

Actual DrawDown %

88.4

Max Drawdown 5-Year %

-96.6

Target Price

9.57

P/E

Forward P/E

PEG

P/S

6.82

P/B

6.04

P/Free Cash Flow

EPS

-1.08

Average EPS Est. Cur. Y​

-0.92

EPS Next Y. (Est.)

-0.63

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-89.12

Relative Volume

0.96

Return on Equity vs Sector %

-106.5

Return on Equity vs Industry %

-90.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.06

EBIT Estimation

Adaptive Biotechnologies Corpor
Sector: Healthcare
Industry: Biotechnology
Employees:
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
stock quote shares ADPT – Adaptive Biotechnologies Corporation Stock Price stock today
news today ADPT – Adaptive Biotechnologies Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch ADPT – Adaptive Biotechnologies Corporation yahoo finance google finance
stock history ADPT – Adaptive Biotechnologies Corporation invest stock market
stock prices ADPT premarket after hours
ticker ADPT fair value insiders trading